Benitec Biopharma Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Benitec Biopharma Inc. on December 12, 2022, covering events occurring on December 9, 2022. The report details the formal implementation of a corporate governance change approved by stockholders at the Annual Meeting held on December 7, 2022.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on a corporate structural amendment and does not contain financial performance data.
Material Changes
The primary material change reported is the amendment to the Company's Amended and Restated Certificate of Incorporation. The total number of authorized shares of common stock was increased from 40,000,000 to 160,000,000. This amendment was filed with the Secretary of State of Delaware and became effective on December 9, 2022.
Guidance, Outlook, and Risks
The filing contains no management commentary regarding future financial guidance, operational outlook, or specific risk factors. The document serves solely to disclose the effective date of the authorized share increase and incorporates by reference the definitive proxy statement filed on October 25, 2022, for further details on the proposal.
Key Facts for Investor Verification
- Authorized common shares increased from 40,000,000 to 160,000,000.
- The amendment became effective on December 9, 2022.
- Stockholders approved the amendment at the Annual Meeting on December 7, 2022.
- Details regarding the rationale and terms are located in the Schedule 14A proxy statement filed on October 25, 2022.